955365-80-7 | 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-2-(prop-2-en-1-yl)pyrazolo[3,4-d]pyrimidin-3-one

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$16.00	$11.00
5mg	95%	in stock	$23.00	$16.00
10mg	95%	in stock	$32.00	$22.00
25mg	95%	in stock	$48.00	$34.00
50mg	95%	in stock	$66.00	$46.00
100mg	95%	in stock	$105.00	$73.00
250mg	95%	in stock	$169.00	$118.00
1g	95%	in stock	$418.00	$292.00
5g	95%	in stock	$1,535.00	$1,074.00

Description

• Catalog Number: AB52885
• Chemical Name: 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-2-(prop-2-en-1-yl)pyrazolo[3,4-d]pyrimidin-3-one
• CAS Number: 955365-80-7
• Molecular Formula: C27H32N8O2
• Molecular Weight: 500.5954
• MDL Number: MFCD17215200
• SMILES: C=CCn1c(=O)c2c(n1c1cccc(n1)C(O)(C)C)nc(nc2)Nc1ccc(cc1)N1CCN(CC1)C

Computed Properties

• Complexity: 795
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 37
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 7
• XLogP3: 3.1

Literature

• Functional kinomics identifies candidate therapeutic targets in head and neck cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20140815

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.

  Cancer discovery 20120601

• MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.

  Molecular cancer therapeutics 20120101

• MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110501

• Targeting Wee1-like protein kinase to treat cancer.

  Drug news & perspectives 20100901

• Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents.

  Current clinical pharmacology 20100801

• MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.

  Cancer biology & therapy 20100401

• Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.

  Molecular cancer therapeutics 20091101